906673-24-3 | 4-((1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)benzonitrile

Packsize	Purity	Availability	Price	Discounted Price
1mg	97%	in stock	$15.00	$10.00
50mg	97%	in stock	$23.00	$16.00
100mg	97%	in stock	$28.00	$20.00
250mg	97%	in stock	$53.00	$37.00
1g	97%	in stock	$114.00	$80.00
5g	97%	in stock	$379.00	$266.00
25g	97%	in stock	$1,334.00	$934.00

Description

• Catalog Number: AH85206
• Chemical Name: 4-((1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)benzonitrile
• CAS Number: 906673-24-3
• Molecular Formula: C14H10BNO3
• Molecular Weight: 251.0451
• MDL Number: MFCD17169940
• SMILES: N#Cc1ccc(cc1)Oc1ccc2c(c1)COB2O

Computed Properties

• Complexity: 361
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 19
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 2

Literature

• Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.

  Drugs of today (Barcelona, Spain : 1998) 20170401

• Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

  Journal of the American Academy of Dermatology 20160901

• Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers.

  American journal of clinical dermatology 20160101

• A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.

  Dermatology online journal 20140516

• Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application.

  Bioorganic & medicinal chemistry letters 20100401

• Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.

  Bioorganic & medicinal chemistry letters 20090415